|
End-of-day quote
Shanghai S.E.
2026-08-24
|
5-day change | 1st Jan Change | ||
| 14.82 CNY | -1.00% |
|
-3.52% | -1.66% |
| 08-24 | Tasly Pharmaceutical to Buy 4 Billion Yuan of Wealth Management Products | MT |
| 08-24 | Tasly Pharmaceutical's Subsidiary Secures Nod to Trial TSL2402 Tablets | MT |
Company Valuation: Tasly Pharmaceutical Group Co., Ltd
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 23,778 | 15,988 | 25,427 | 21,603 | 22,514 | 22,140 | - | - |
| Change | - | -32.76% | 59.04% | -15.04% | 4.22% | -1.66% | - | - |
| Enterprise Value (EV) 1 | 23,086 | 14,968 | 23,635 | 20,197 | 22,465 | 20,596 | 16,428 | 19,771 |
| Change | - | -35.16% | 57.9% | -14.55% | 11.23% | -8.32% | -20.24% | 20.35% |
| P/E | 10.1x | -63.3x | 23.6x | 22.6x | 20.4x | 16.4x | 13.7x | 12.1x |
| PBR | 1.83x | 1.3x | 2.06x | 1.81x | 1.82x | 1.66x | 1.53x | 1.41x |
| PEG | - | 1x | -0x | -2x | 1.3x | 0.7x | 0.7x | 0.9x |
| Capitalization / Revenue | 2.99x | 1.86x | 2.93x | 2.54x | 2.73x | 2.55x | 2.32x | 2.11x |
| EV / Revenue | 2.9x | 1.74x | 2.72x | 2.38x | 2.73x | 2.37x | 1.72x | 1.88x |
| EV / EBITDA | 7.32x | 50.8x | 14.2x | 12.8x | 12.3x | 9.81x | 6.85x | 7.48x |
| EV / EBIT | 8.45x | -97.9x | 19.2x | 18.8x | 16.6x | 12.9x | 9.11x | 9.72x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.33 | 0.33 | 0.33 | 0.2 | 0.1 | 0.4128 | 0.5161 | 0.5783 |
| Rate of return | 2.08% | 3.07% | 1.94% | 1.38% | 0.66% | 2.79% | 3.48% | 3.9% |
| EPS 2 | 1.57 | -0.17 | 0.72 | 0.64 | 0.74 | 0.9044 | 1.082 | 1.222 |
| Distribution rate | 21% | -194% | 45.8% | 31.3% | 13.5% | 45.6% | 47.7% | 47.3% |
| Net sales 1 | 7,952 | 8,593 | 8,674 | 8,498 | 8,236 | 8,675 | 9,556 | 10,497 |
| EBITDA 1 | 3,153 | 294.6 | 1,663 | 1,578 | 1,820 | 2,100 | 2,397 | 2,645 |
| EBIT 1 | 2,733 | -153 | 1,228 | 1,076 | 1,350 | 1,595 | 1,803 | 2,033 |
| Net income 1 | 2,359 | -256.5 | 1,071 | 955.6 | 1,105 | 1,353 | 1,616 | 1,827 |
| Net Debt 1 | -691.9 | -1,020 | -1,792 | -1,406 | -48.5 | -1,544 | -5,712 | -2,369 |
| Reference price 2 | 15.85 | 10.76 | 17.02 | 14.46 | 15.07 | 14.82 | 14.82 | 14.82 |
| Nbr of stocks (in thousands) | 1,500,163 | 1,485,873 | 1,493,950 | 1,493,950 | 1,493,950 | 1,493,950 | - | - |
| Announcement Date | 3/30/22 | 3/27/23 | 4/15/24 | 2/24/25 | 2/6/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 16.57x | 2.38x | 9.99x | 3.07% | 3.29B | |
| 15.56x | 1.85x | 12.51x | 5.5% | 13.14B | |
| 22.22x | 1.42x | 8.53x | 2.86% | 4.85B | |
| 15.99x | 2.92x | 8.97x | 5.31% | 4.56B | |
| 18.28x | - | - | 1.28% | 3.94B | |
| 26.38x | - | - | - | 3.54B | |
| 13.29x | 2.72x | 11.14x | 6.14% | 1.65B | |
| Average | 18.33x | 2.26x | 10.23x | 4.03% | 4.99B | |
| Weighted average by Cap. | 17.93x | 2.07x | 10.84x | 4.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 600535 Stock
- Valuation Tasly Pharmaceutical Group Co., Ltd
Select your edition
All financial news and data tailored to specific country editions
